CA2738024A1 - Methods for purification of viruses - Google Patents

Methods for purification of viruses Download PDF

Info

Publication number
CA2738024A1
CA2738024A1 CA2738024A CA2738024A CA2738024A1 CA 2738024 A1 CA2738024 A1 CA 2738024A1 CA 2738024 A CA2738024 A CA 2738024A CA 2738024 A CA2738024 A CA 2738024A CA 2738024 A1 CA2738024 A1 CA 2738024A1
Authority
CA
Canada
Prior art keywords
virus
cells
cell
viruses
specific embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2738024A
Other languages
English (en)
French (fr)
Inventor
Mark Thompson
Janice Wee
Akanksha Nagpal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CA2738024A1 publication Critical patent/CA2738024A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2738024A 2008-09-24 2009-09-24 Methods for purification of viruses Abandoned CA2738024A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US9974908P 2008-09-24 2008-09-24
US61/099,749 2008-09-24
US10493308P 2008-10-13 2008-10-13
US61/104,933 2008-10-13
US12245608P 2008-12-15 2008-12-15
US61/122,456 2008-12-15
US18772109P 2009-06-17 2009-06-17
US61/187,721 2009-06-17
US22213109P 2009-07-01 2009-07-01
US61/222,131 2009-07-01
PCT/US2009/058174 WO2010036774A1 (en) 2008-09-24 2009-09-24 Methods for purification of viruses

Publications (1)

Publication Number Publication Date
CA2738024A1 true CA2738024A1 (en) 2010-04-01

Family

ID=42060079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2738024A Abandoned CA2738024A1 (en) 2008-09-24 2009-09-24 Methods for purification of viruses

Country Status (9)

Country Link
US (1) US8785173B2 (enExample)
EP (1) EP2334328A4 (enExample)
JP (1) JP5548207B2 (enExample)
KR (1) KR20110074563A (enExample)
CN (1) CN102215865B (enExample)
AU (1) AU2009296628B2 (enExample)
BR (1) BRPI0919250A2 (enExample)
CA (1) CA2738024A1 (enExample)
WO (1) WO2010036774A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189326B (zh) 2004-12-23 2013-06-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
EP2069480B1 (en) 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
CN103952376A (zh) 2008-09-24 2014-07-30 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
JP5548207B2 (ja) 2008-09-24 2014-07-16 メディミューン,エルエルシー ウイルスの精製方法
AU2011262309B2 (en) * 2010-06-01 2015-08-13 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
EP2598223B1 (en) 2010-07-30 2022-04-06 EMD Millipore Corporation Chromatography media and method
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US9611458B2 (en) 2010-12-27 2017-04-04 Kyowa Hakko Kirin Co., Ltd Method for preparing aqueous solution containing culture medium and chelating agent
CN102199198A (zh) * 2011-03-28 2011-09-28 北京交通大学 人呼吸道合胞病毒f蛋白的纯化方法
ES2653197T3 (es) * 2011-07-20 2018-02-06 Bgp Products B.V. Procedimiento para producir antígeno ortomixoviral y vacunas
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
MX383879B (es) * 2014-05-13 2025-03-14 Amgen Inc Sistema y métodos de control del proceso para usar con filtros y procesos de filtración.
SG11201700030UA (en) 2014-09-02 2017-02-27 Emd Millipore Corp High surface area fiber media with nano-fibrillated surface features
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3353193A4 (en) * 2015-09-22 2019-04-03 Sanofi Pasteur Biologics, LLC CLEANING OF THE RESPIRATORY SYNZYTIAL VIRUS
CN106337045A (zh) * 2016-05-24 2017-01-18 微基生物科技(上海)有限公司 一种防止pcr污染的方法及其应用
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
EP3601543A4 (en) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
GEP20237575B (en) * 2017-10-16 2023-12-25 Serum Institute Of India Pvt Ltd Stable vaccine compositions comprising inter alia live attenuated recombinant dengue virus and process for preparation thereof
WO2019092084A1 (en) * 2017-11-08 2019-05-16 Blue Sky Vaccines Gmbh So3 chromatography for use in a method for virus purification
CN111447947B (zh) 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
US10988726B2 (en) 2018-08-19 2021-04-27 Cytera Cellworks Limited Systems and methods for automated cell culturing
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
CN113330111A (zh) * 2018-11-21 2021-08-31 西方溶瘤细胞有限公司 病毒的制造
CN111763661B (zh) * 2019-04-02 2022-07-29 普莱柯生物工程股份有限公司 一种病毒纯化的方法、制备的疫苗组合物及其应用
JP7712284B2 (ja) * 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物
CN115698305A (zh) * 2020-06-11 2023-02-03 2赛文缇生物公司 用于制造病毒载体的方法
JP2023530445A (ja) * 2020-06-17 2023-07-18 メイッサ ヴァクシーン,インコーポレイテッド キメラrsvおよびコロナウイルスタンパク質、免疫原性組成物、ならびに使用方法
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
JP7716233B2 (ja) * 2021-05-28 2025-07-31 ダイセン・メンブレン・システムズ株式会社 微小有用物質の分離精製方法と分離精製装置
CN113930353B (zh) * 2021-08-31 2023-07-07 广西大学 一种耐亚硒酸盐的粘质沙雷氏菌及其还原特性鉴定方法
JP7764758B2 (ja) 2021-12-27 2025-11-06 株式会社島津製作所 濃縮装置、それを備えた分析システムおよび濃縮方法
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN115505571B (zh) * 2022-11-24 2023-03-10 上海倍谙基生物科技有限公司 适用于悬浮培养lmh细胞生产禽腺病毒的无血清添加剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5118513A (en) 1987-07-02 1992-06-02 The Procter & Gamble Company Method for enhancing bioavailability of iron-calcium mineral supplements
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US20060019350A1 (en) 1989-08-28 2006-01-26 Peter Palese Recombinant negative strand RNA virus expression system and vacccines
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6245549B1 (en) * 1990-06-28 2001-06-12 Connaught Laboratories Limited Production of virus and purification of viral envelope proteins for vaccine use
GB9215834D0 (en) 1992-07-24 1992-09-09 Celltech Ltd Cell culture
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
AU732703B2 (en) 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1210410B1 (en) 1999-08-27 2008-01-16 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
DE60137345D1 (de) 2000-04-28 2009-02-26 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
WO2002002752A1 (en) 2000-06-23 2002-01-10 Akzo Nobel N.V. Attenuated bovine respiratory syncytial virus
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
CA2477037C (en) 2002-02-21 2014-12-09 Mount Sinai School Of Medicine Recombinant negative strand virus rna expression systems and vaccines
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US20050158342A1 (en) 2003-12-23 2005-07-21 Medimmune, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540613A (zh) 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
ATE427990T1 (de) 2002-04-30 2009-04-15 Oncolytics Biotech Inc Verbesserte reinigungsmethode fur viren
US6825306B2 (en) 2002-08-16 2004-11-30 The Goodyear Tire & Rubber Company Functionalized monomers for synthesis of rubbery polymers
JP2004135665A (ja) 2002-09-25 2004-05-13 Nihon Pharmaceutical Co Ltd ウイルスの分離法
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
EP1597400B8 (en) 2003-02-25 2013-10-09 MedImmune, LLC Methods of producing influenza vaccine compositions
US7687240B2 (en) * 2003-03-18 2010-03-30 Wyeth Holdings Corporation Process for increasing RSV surface glycoprotein yields using a mutant strain of RSV
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ,インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
JP2006525815A (ja) 2003-05-28 2006-11-16 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション Poliiプロモーターおよびリボザイムを有する組換えインフルエンザベクター
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
KR101346989B1 (ko) 2004-10-06 2014-02-06 메디뮨 엘엘씨 냉장 온도 안정성 인플루엔자 백신 조성물
CN101189326B (zh) * 2004-12-23 2013-06-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CA2613284A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral rna in canine cells
AU2007240448B8 (en) 2006-04-19 2014-03-06 Medimmune Llc. Methods and compositions for expressing negative-sense viral RNA in canine cells
US7875446B2 (en) 2006-04-20 2011-01-25 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
EP2069480B1 (en) 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
JP5548207B2 (ja) 2008-09-24 2014-07-16 メディミューン,エルエルシー ウイルスの精製方法
CN103952376A (zh) 2008-09-24 2014-07-30 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法

Also Published As

Publication number Publication date
EP2334328A1 (en) 2011-06-22
JP5548207B2 (ja) 2014-07-16
AU2009296628A1 (en) 2010-04-01
CN102215865A (zh) 2011-10-12
US8785173B2 (en) 2014-07-22
JP2012503489A (ja) 2012-02-09
US20120219588A1 (en) 2012-08-30
AU2009296628B2 (en) 2015-01-15
WO2010036774A1 (en) 2010-04-01
EP2334328A4 (en) 2012-08-29
CN102215865B (zh) 2013-10-30
BRPI0919250A2 (pt) 2015-12-15
KR20110074563A (ko) 2011-06-30

Similar Documents

Publication Publication Date Title
US8785173B2 (en) Methods for purification of viruses
US8202726B2 (en) Methods for cultivating cells, propagating and purifying viruses
US8357376B2 (en) Method of purifying influenza virus and removing MDCK cell DNA contaminants
AU2013224732A1 (en) Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
HK1187373A (en) Method for eliminating dna contaminants from viral preparations
HK1133904A (en) Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
HK1133904B (en) Mdck cell lines supporting viral growth to high titers and bioreactor process using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140825

FZDE Discontinued

Effective date: 20170926